COVID-19: a case for inhibiting IL-17?

IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to prevent acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) and discuss why we think that a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacha, Omar, Sallman, Mary Alice, Evans, Scott E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194244/
https://www.ncbi.nlm.nih.gov/pubmed/32358580
http://dx.doi.org/10.1038/s41577-020-0328-z
_version_ 1783528314510508032
author Pacha, Omar
Sallman, Mary Alice
Evans, Scott E.
author_facet Pacha, Omar
Sallman, Mary Alice
Evans, Scott E.
author_sort Pacha, Omar
collection PubMed
description IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to prevent acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) and discuss why we think that a clinical trial of a drug in this class could be a logical addition to the effort to find effective therapies.
format Online
Article
Text
id pubmed-7194244
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71942442020-05-02 COVID-19: a case for inhibiting IL-17? Pacha, Omar Sallman, Mary Alice Evans, Scott E. Nat Rev Immunol Comment IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to prevent acute respiratory distress syndrome (ARDS) in coronavirus disease 2019 (COVID-19) and discuss why we think that a clinical trial of a drug in this class could be a logical addition to the effort to find effective therapies. Nature Publishing Group UK 2020-05-01 2020 /pmc/articles/PMC7194244/ /pubmed/32358580 http://dx.doi.org/10.1038/s41577-020-0328-z Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Pacha, Omar
Sallman, Mary Alice
Evans, Scott E.
COVID-19: a case for inhibiting IL-17?
title COVID-19: a case for inhibiting IL-17?
title_full COVID-19: a case for inhibiting IL-17?
title_fullStr COVID-19: a case for inhibiting IL-17?
title_full_unstemmed COVID-19: a case for inhibiting IL-17?
title_short COVID-19: a case for inhibiting IL-17?
title_sort covid-19: a case for inhibiting il-17?
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194244/
https://www.ncbi.nlm.nih.gov/pubmed/32358580
http://dx.doi.org/10.1038/s41577-020-0328-z
work_keys_str_mv AT pachaomar covid19acaseforinhibitingil17
AT sallmanmaryalice covid19acaseforinhibitingil17
AT evansscotte covid19acaseforinhibitingil17

Ejemplares similares